Newborn Screening and Birth Prevalence for Spinal Muscular Atrophy in the US

Authors:

Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive disease resulting in progressive motor neuron death, muscle denervation, and weakness.1 Rapid, widespread implementation of newborn screening (NBS) for SMA in the US since 2018 has facilitated the collection of precise SMA data, including birth prevalence.2 Cure SMA, a US-based patient advocacy organization supporting people with SMA, partnered with state public health laboratories (PHLs) to collect data on infants who were screened for SMA and confirmed to have SMA diagnosis. This study estimated the birth prevalence of SMA and evaluated the distribution of SMN2 copy number in US newborns with SMA.